Work

Phase II trial of opaganib in patients with metastatic castration-resistant prostate cancer progressing on abiraterone or enzalutamide (NCT04207255).

Year: 2021

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2021.39.6_suppl.tps191

Authors: Omer Kucuk, Charles Smith, Terry Plasse, Besim Ogretmen, Shikhar Mehrotra, Theodore Stewart Gourdin, Mehmet Asim Bilen, Bradley Curtis Carthon, Bassel Nazha, Jamie Goldman, Michael B. Lilly

Institutions: Winship Cancer Institute, Apogee Biotechnology (United States), Medical University of South Carolina, MUSC Hollings Cancer Center, Emory University, Emory University Hospital Midtown

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: National Institutes of Health

OpenAlex ID: W3133566894

Cites:

Cited by: 3

Related to: 10